Alex Herrera, MD
Hematology · Duarte, CANPI 1275761553
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $130,527 of the $155,332 with a category attached, or 84.0%. It is spread thinly across 27 manufacturers, the largest accounting for just 22.2%.
Across 145 payments — averaging $1071.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$34K
- Seagen Inc.$23K
- Takeda Pharmaceuticals U.S.A., Inc.$14K
- F. Hoffmann-la Roche AG$14K
- AstraZeneca$11K
- Astrazeneca UK Limited$9K
- plus $51K from 21 others
Across 494 payments — averaging $102,812 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$16.1M
- E.r. Squibb & Sons, L.L.C.$12.9M
- Merck$11.9M
- Pfizer$6.4M
- Genentech, Inc.$2.5M
- Gilead$237K
- plus $702K from 8 others
What the payments were for
- Consulting fees$130,52784%
- Speaking & faculty fees$17,65211%
- Travel & lodging$2,4182%
- Food & beverage$4,7253%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 19 | $34,465 |
| Seagen Inc. | 20 | $23,396 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $13,699 |
| F. Hoffmann-la Roche AG | 18 | $13,606 |
| AstraZeneca | 13 | $10,909 |
| Astrazeneca UK Limited | 5 | $8,583 |
| Pfizer | 4 | $7,915 |
| ADC Therapeutics America, Inc. | 3 | $6,620 |
| Roche Sequencing Solutions, Inc. | 1 | $5,000 |
| AbbVie | 10 | $4,906 |
| Karyopharm Therapeutics Inc. | 3 | $3,513 |
| Merck | 2 | $3,330 |
| Eli Lilly | 4 | $3,295 |
| Bristol Myers Squibb | 7 | $3,260 |
| Genentech USA, Inc. | 7 | $3,028 |
| Regeneron | 1 | $2,620 |
| Genmab U.S., Inc. | 3 | $2,385 |
| Incyte Corporation | 3 | $2,225 |
| Genentech, Inc. | 5 | $1,751 |
| Gilead(2 entities) | 3 | $187 |
| Beigene USA, Inc. | 2 | $175 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $149 |
| Morphosys, US Inc. | 1 | $138 |
| Novartis | 1 | $95 |
| Lilly USA, LLC | 3 | $45 |
| Beone Medicines USA, Inc. | 1 | $27 |
| Epizyme, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$155,332 in reported general payments places this provider in the 85th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $80 |
Paid to pharmacies, not to this prescriber.
Other hematology in Duarte
- Amrita KrishnanDuarte$671K
- Vinod PullarkatDuarte$576K
- Alexey DanilovDuarte$407K
- Tycel PhillipsDuarte$348K
- Haris AliDuarte$310K
- Amandeep SalhotraDuarte$214K
- Tanya SiddiqiDuarte$199K
- Scott GoldsmithDuarte$180K
- Ibrahim AldossDuarte$175K
- Geoffrey ShouseDuarte$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.